Skip to content

Controlled ovarian stimulation with highly purified menotropin in low-responder patients.

Comparison of two protocols of controlled ovarian stimulation with highly purified menotropin in low-responder patients according to Bologna criteria treated in Spanish public hospitals.

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2016-001590-32-ES
Enrollment
64
Registered
2018-02-08
Start date
2018-04-19
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PRIMARY INFERTILITY MedDRA version: 20.1 Level: LLT Classification code 10016399 Term: Female infertility (primary) System Organ Class: 100000004872

Interventions

Trade Name: MENOPUR Pharmaceutical Form: Powder and solution for solution for injection INN or Proposed INN: GONADOTROPINA (MENOTROPINA ALTAMENTE PURIFICADA) CAS Number: 61489-71-2 Other descriptive n

Sponsors

Manuel Macía Cortiñas
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who initiate COS therapy with GnRH agonist and ICSI. 2. Age =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Endometriosis or uterine malformation 2. PCOS according to Rotterdam criteria 3. Presence of hydrosalping 4. Intolerance or allergy to drugs 5. Moderate or severe male factor

Design outcomes

Primary

MeasureTime frame
Main Objective: Improvement of the ovarian response.;Secondary Objective: Pregnancy rate Follicular development Serum hormonal profile at the beginning of the stimulation, in W5 and in the day of the ovulatory discharge Safety of the treatment.;Primary end point(s): Improvement of the ovarian response.;Timepoint(s) of evaluation of this end point: 6 weeks

Secondary

MeasureTime frame
Secondary end point(s): Pregnancy rate Follicular development Serum hormonal profile at the start of the stimulation, at W5 and on the day of ovulatory discharge Safety Profile;Timepoint(s) of evaluation of this end point: 6 weeks

Countries

Spain

Contacts

Public ContactClinical Operations Department

APICES SOLUCIONES SL

ana.moreno@apices.es0034918166804100

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026